Ticker Details
Prelude Therapeutics Inc.
IPO Date:	September 25, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$277.21M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.53 | 4.58%
Avg Daily Range (30 D):	$0.17 | 5.06%
Avg Daily Range (90 D):	$0.14 | 5.70%

Institutional Daily Volume
Avg Daily Volume:	.21M
Avg Daily Volume (30 D):	.19M
Avg Daily Volume (90 D):	.3M

Trade Size
Avg Trade Size (Sh.):	113
Avg Trade Size (Sh.) (30 D):	91
Avg Trade Size (Sh.) (90 D):	124

Institutional Trades
Total Institutional Trades:	335
Avg Institutional Trade:	$1.97M
Avg Institutional Trade (30 D):	$1.11M
Avg Institutional Trade (90 D):	$1.11M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.35M
Avg Closing Trade (30 D):	$.55M
Avg Closing Trade (90 D):	$.55M
Avg Closing Volume:	88.73K

News

Dec 6, 2025 @ 4:00 PM Prelude Therapeutics Presents Data at the 2025 ASH... Source: Prelude Therapeutics

Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai

Sep 13, 2024 @ 2:00 PM Prelude Therapeutics’ SMARCA2 Degrader PRT3... Source: Prelude Therapeutics Incorporated

Jun 3, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Upcoming He... Source: Prelude Therapeutics, Inc.

May 9, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Citizens JM... Source: Prelude Therapeutics, Inc.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.29	$-.2	$-1.29
Diluted EPS	$-1.29	$-.2	$-1.29
Revenue	$12.14M	$5.64M	$12.14M
Gross Profit
Net Income / Loss	$-99.5M	$-16.46M	$-99.5M
Operating Income / Loss	$-104.57M	$-17.35M	$-104.57M
Cost of Revenue
Net Cash Flow	$21.97M	$-12.28M	$21.97M
PE Ratio